Not too late to buy Mannkind. MNKD. GOOD NEWS ahead the next week on buyout or partnership.
--and a beautiful day to all! At four hours before the bell futures marts have stocks up & metals down;
IBD ratings--
MANNKIND CORP RANK WITHIN THE MEDICAL-BIOMED/BIOTECH GROUP (324 STOCKS)
- Composite Rating 57 Rank within Group: 39th
88%- EPS Rating 33 Rank within Group: 102nd
68%- Relative Strength Rating 98 Rank within Group: 16th
95%- SMR Rating(N/A) Rank within Group: N/A
N/A- Acc/Dist. Rating B- Rank within Group: 103rd
68%
Let's see what happens, be a good test of IBD...